Aurobindo Pharma is reportedly in discussion with global pharma giant Actavis to buy their Active Pharmaceutical Ingredients (API) units in Western Europe. The move is in line with the Aurobindo’s strategy to vertically integrate their injectables business by buying ingredient making units.
Actavis is likely to sell loss making units in Italy, Spain, France, Germany and the Netherlands. The API units have revenue of close to $500 million.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
Actavis is likely to sell loss making units in Italy, Spain, France, Germany and the Netherlands. The API units have revenue of close to $500 million.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
No comments:
Post a Comment